Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.56
(3.41%)
CAD 14.56
(3.41%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 353 Thousand USD | -17.52% |
| 2022 | 428 Thousand USD | -17.05% |
| 2021 | 516 Thousand USD | -72.09% |
| 2020 | 1.84 Million USD | -80.68% |
| 2019 | 9.56 Million USD | -45.54% |
| 2018 | 17.56 Million USD | -3.04% |
| 2017 | 18.12 Million USD | -50.19% |
| 2016 | 36.37 Million USD | 5.2% |
| 2015 | 34.57 Million USD | 4980.23% |
| 2014 | 680.63 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 1.13 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 323 Thousand USD | -8.5% |
| 2024 Q2 | 296 Thousand USD | -8.36% |
| 2023 Q4 | 353 Thousand USD | 0.0% |
| 2023 Q3 | 353 Thousand USD | -8.55% |
| 2023 FY | 353 Thousand USD | -17.52% |
| 2023 Q1 | 403 Thousand USD | -5.84% |
| 2023 Q2 | 386 Thousand USD | -4.22% |
| 2022 Q4 | 428 Thousand USD | -4.04% |
| 2022 FY | 428 Thousand USD | -17.05% |
| 2022 Q1 | 524 Thousand USD | 1.55% |
| 2022 Q2 | 507 Thousand USD | -3.24% |
| 2022 Q3 | 446 Thousand USD | -12.03% |
| 2021 Q3 | - USD | -100.0% |
| 2021 FY | 516 Thousand USD | -72.09% |
| 2021 Q2 | 1.87 Million USD | 1.9% |
| 2021 Q4 | 516 Thousand USD | 0.0% |
| 2021 Q1 | 1.84 Million USD | -0.43% |
| 2020 Q1 | 7.39 Million USD | -22.71% |
| 2020 Q3 | 3.46 Million USD | -36.39% |
| 2020 Q4 | 1.84 Million USD | -46.56% |
| 2020 FY | 1.84 Million USD | -80.68% |
| 2020 Q2 | 5.43 Million USD | -26.45% |
| 2019 Q1 | 15.53 Million USD | -11.58% |
| 2019 Q4 | 9.56 Million USD | -24.7% |
| 2019 Q3 | 12.7 Million USD | -24.75% |
| 2019 Q2 | 16.88 Million USD | 8.7% |
| 2019 FY | 9.56 Million USD | -45.54% |
| 2018 Q2 | 21.48 Million USD | 30.28% |
| 2018 FY | 17.56 Million USD | -3.04% |
| 2018 Q4 | 17.56 Million USD | -9.72% |
| 2018 Q3 | 19.46 Million USD | -9.41% |
| 2018 Q1 | 16.49 Million USD | -9.0% |
| 2017 FY | 18.12 Million USD | -50.19% |
| 2017 Q4 | 18.12 Million USD | -8.13% |
| 2017 Q2 | 19.61 Million USD | -50.35% |
| 2017 Q1 | 39.5 Million USD | 8.59% |
| 2017 Q3 | 19.72 Million USD | 0.58% |
| 2016 FY | 36.37 Million USD | 5.2% |
| 2016 Q2 | 35.17 Million USD | 0.85% |
| 2016 Q3 | 35.98 Million USD | 2.3% |
| 2016 Q4 | 36.37 Million USD | 1.1% |
| 2016 Q1 | 34.87 Million USD | 0.85% |
| 2015 FY | 34.57 Million USD | 4980.23% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | 34.57 Million USD | 0.58% |
| 2015 Q3 | 34.37 Million USD | 1.51% |
| 2015 Q2 | 33.86 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 680.63 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | 146.21 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | -100.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q2 | 838.6 Thousand USD | -20.72% |
| 2004 Q1 | 1.05 Million USD | 0.0% |
| 2004 FY | 1.13 Million USD | 0.0% |
| 2004 Q3 | 682.68 Thousand USD | -18.59% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | 104.79 Million CAD | 99.663% |
| Avicanna Inc. | 1.8 Million CAD | 80.426% |
| Avant Brands Inc. | 18.7 Million CAD | 98.113% |
| Cardiol Therapeutics Inc. | 158.53 Thousand CAD | -122.668% |
| Crescita Therapeutics Inc. | 1.25 Million CAD | 71.85% |
| Knight Therapeutics Inc. | 69.09 Million CAD | 99.489% |
| MediPharm Labs Corp. | 2.29 Million CAD | 84.619% |
| OrganiGram Holdings Inc. | 155 Thousand CAD | -127.742% |
| Canopy Growth Corporation | 683.17 Million CAD | 99.948% |
| Willow Biosciences Inc. | 2.15 Million CAD | 83.627% |
| Auxly Cannabis Group Inc. | 159.04 Million CAD | 99.778% |